BlueWind scores CE mark for neuropathic pain neurostimulator

BlueWind Medical has won a CE mark for its miniature neurostimulation implant to treat peripheral neuropathic pain. The approval comes three months after the Israeli startup received a CE mark for its neurostimulator to treat overactive bladder.

The wireless, batteryless Vivendi neurostimulator is 90% smaller than neurostimulators currently on the market, according to the company. It is implanted near the tibial nerve during a minimally invasive procedure that takes 30 minutes, BlueWind said in a statement. powered by an external unit worn on the patient’s ankle, the device stimulates the nerve to alleviate pain. Because it’s batteryless, the patient does not need to undergo further surgeries to replace the device.

Patients use the external component to self-administer the treatment as needed. Pain reduction is usually immediate, BlueWind said, and lasts between 30 minutes and a few hours. In a clinical study involving 13 patients in Europe, 80% of patients reported a more than 50% decrease in VAS pain scores over 6 months after implantation.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Peripheral neuropathic pain affects about 8 million people in Europe and 6 million in the U.S., BlueWind said. It is most commonly treated with drugs, including opioids. An alternative, nonpharmacological treatment such as neurostimulation could help cut down on the intensive use of opioids to treat the condition.

"Until today, it was not possible to locally treat chronic peripheral pain with neurostimulators due to the size and complexity of existing neurostimulators. BlueWind's miniature and wireless neurostimulators are significantly smaller, allow for a simple implant procedure, precise targeting of the pain location, and are easier for patients to use at home,” said BlueWind CEO Guri Oron in the statement.

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.